$100B Bonanza: Pfizer Reports Record Sales, Profits Behind COVID Vaccine, Oral Treatment

Pfizer reaped record sales and profits in 2022, as the pharmaceutical giant’s COVID vaccine and oral treatment helped bring in revenues that topped $100 billion.

On Tuesday, the Securities and Exchange Commission, the Manhattan-based company reported a profit of $31 billion, up 43% over 2021. It claimed it paid $9 billion in dividends to shareholders and that it spent $2 billion on its stock buybacks.

“2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history,” The report included statements by Dr. Albert Bourla, Chairman and Chief Executive Officer.

The $100 billion in sales was up $19 billion over 2021, and Pfizer’s operational growth was “driven primarily” The filing stated that the COVID vaccine, called Comirnaty, and the oral COVID treatment, Paxlovid were both included in the filing.

Even as COVID boosters have had mixed results in stopping the contraction and spread of COVID–and have been linked to “adverse reactions” which can be more serious than the risk of COVID itself–Pfizer expects to make billions on COVID products in the upcoming year.

Pfizer predicts that Comirnaty will represent 24% of the U.S. populaiton. “receive a vaccine” Each person receiving 1.3 doses will get a minimum of one dose in 2023. Pfizer is expected to dominate 64% of the market, which will result in $13.5 billion in revenue. That’s down 64% compared to 2022, due to expected “lower compliance.”

However, Pfizer’s own calculations seem to suggest little confidence in the vaccine’s ability to prevent infection. It predicts that more people will develop COVID in 2023 as a result of the vaccine. “waning of population immune protection due to reduced vaccination rates”–but the increase in expected symptomatic COVID cases is negligible, from 110 million to 112 million worldwide (excluding China). According to the company, the vaccine reduces the severity of infection and decreases the chance of hospitalization.

Pfizer claims that 17% will receive an oral antiviral medication. The market is 90% dominated by Paxlovid, which the company estimates. Pfizer expects to make $8 billion in revenue from that deal in 2023. The U.S. Government agreed to buy approximately 24 million doses Paxlovid. Part of the deal was made in December, despite the fact that the Food and Drug Administration had inked the deal in December. “extended the review period” for its New Drug Application. It said that although Pfizer currently has limited ability to market Paxlovid, it is expecting a government decision soon.

Worldwide, revenues from COVID vaccines and treatments dwarfed those of Pfizer’s other biopharmaceutical products, totaling $57 billion, with all of its cancer treatments combined bringing in only $12 billion.

The sales of the vaccine are expected to increase by 2022 “emerging markets” Africa saw a decline in its value from $11.4 billion to $9.9B in 2021, while it grew in “developed Europe” From $9.3 billion up to $10.8 billion, and in the “developed rest of the world” From $8.1 billion to 8.3 bilion The U.S. saw sales rise from $7.8 billion up to $8.7billion.

In “Risks Related to Our Business, Industry and Operations, and Business Development,” Pfizer noted “the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data” “the risk that more widespread use of Comirnaty, the Pfizer-BioNTech COVID-19 bivalent vaccine or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious.”

This month, Project Veritas released video in which a man it identified as Jordon Trishton Walker, Pfizer’s director of research and development, strategic operations – mRNA scientific planner, Physically skirmished with the undercover journalism group’s founder in order to take in iPad which contained video of Walker saying that the company was considering “directed evolution” The virus.

“One of the things we’re exploring is like, why don’t we just mutate it [COVID] ourselves so we could create — preemptively develop new vaccines, right?” He stated.

“Don’t tell anyone. Promise you won’t tell anyone,” He concluded. “The way it [the experiment] would work is that we put the virus in monkeys, and we successively cause them to keep infecting each other, and we collect serial samples from them.”

The video was not addressed by the company, however. A statement that “In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.”